Detalhe da pesquisa
1.
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
BioDrugs
; 37(1): 89-98, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36417156
2.
BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.
Front Oncol
; 13: 1211759, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37576888
3.
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Cancer Med
; 12(22): 20847-20863, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935428
4.
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Cancer Cell
; 1(5): 421-32, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12124172
5.
Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design.
Eur J Med Chem
; 229: 114043, 2022 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34929581
6.
Large-scale production, purification, and function of a tumor multi-epitope vaccine: Peptibody with bFGF/VEGFA.
Eng Life Sci
; 20(9-10): 422-436, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32944017
7.
Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
Bioorg Med Chem Lett
; 19(14): 3836-40, 2009 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19410458
8.
A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects.
BioDrugs
; 33(3): 335-342, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016568
9.
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
J Med Chem
; 46(23): 4910-25, 2003 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-14584942
10.
Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
J Med Chem
; 45(20): 4513-23, 2002 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-12238930
11.
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
J Med Chem
; 45(17): 3772-93, 2002 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12166950
12.
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.
J Med Chem
; 45(14): 3057-66, 2002 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-12086491
13.
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Blood
; 108(4): 1339-45, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16627759
14.
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Bioorg Med Chem Lett
; 13(18): 3001-4, 2003 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12941321
15.
Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
Bioorg Med Chem Lett
; 14(19): 4867-72, 2004 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-15341941
16.
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Blood
; 104(9): 2867-72, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15256420
17.
Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.
Am J Pathol
; 161(4): 1395-407, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12368212